ALK and non-small cell lung carcinoma: During an fifteen-month follow-up, no recurrence of the disease was detected.These results indicate that ensartinib may provide potential benefit for patients with locally advanced ALK-positive NSCLC by optimizing surgical feasibility and survival outcomes.